|
|
Article: FibroGen Announces New Research on HIF-PHI and Anti-CTGF Development Programs in Chronic Kidney Disease.
- Article from:
- Business Wire
- Article date:
- November 10, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data Presented at the 41(st) Annual Meeting of the American Society of Nephrology
SOUTH SAN FRANCISCO, Calif. -- FibroGen, Inc. today announced data from research on its therapeutic programs related to hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHI) and anti-connective tissue growth factor (anti-CTGF) were reported at the 41st annual meeting of the American Society of Nephrology (ASN) Renal Week November 6-9, 2008, in Philadelphia, PA.
HIF-PHI Anemia Research Presented at Renal Week
There were two presentations on FibroGen's oral HIF-PH inhibitors, FG-2216 and FG-4592, investigational drugs designed to stimulate ...